Journal of Neuro-Oncology

, Volume 111, Issue 2, pp 153–161 | Cite as

Real-time multi-modality imaging of glioblastoma tumor resection and recurrence

  • Shawn Hingtgen
  • Jose-Luiz Figueiredo
  • Christian Farrar
  • Matthias Duebgen
  • Jordi Martinez-Quintanilla
  • Deepak Bhere
  • Khalid ShahEmail author
Laboratory Investigation


The lack of relevant pre-clinical animal models incorporating the clinical scenario of Glioblastoma multiforme (GBM) resection and recurrence has contributed significantly to the inability to successfully treat GBM. A multi-modality imaging approach that allows real-time assessment of tumor resection during surgery and non-invasive detection of post-operative tumor volumes is urgently needed. In this study, we report the development and implementation of an optical imaging and magnetic resonance imaging (MRI) approach to guide GBM resection during surgery and track tumor recurrence at multiple resolutions in mice. Intra-operative fluorescence-guided surgery allowed real-time monitoring of intracranial tumor removal and led to greater than 90 % removal of established intracranial human GBM. The fluorescent signal clearly delineated tumor margins, residual tumor, and correlated closely with the clinically utilized fluorescence surgical marker 5-aminolevulinic acid/porphyrin. Post-operative non-invasive optical imaging and MRI confirmed near-complete tumor removal, which was further validated by immunohistochemistry (IHC). Longitudinal non-invasive imaging and IHC showed rapid recurrence of multi-focal tumors that exhibited a faster growth rate and altered blood-vessel density compared to non-resected tumors. Surgical tumor resection significantly extended long-term survival, however mice ultimately succumbed to the recurrent GBM. This multi-modality imaging approach to GBM resection and recurrence in mice should provide an important platform for investigating multiple aspects of GBM and ultimately evaluating novel therapeutics.


Glioma Image-Guided resection In vivo imaging Recurrence 



This work was supported by Alliance for Cancer Cell and Gene Therapy (KS), American Cancer Society (KS), James McDonald Foundation (KS) and National Institute of Health, R01-NSO71197 (KS).

Conflict of interest

The authors have no conflicts to disclose.

Supplementary material

11060_2012_1008_MOESM1_ESM.tif (1.4 mb)
Supplemental Figure 1 Pre-resection tumor progression. Representative images and summary data demonstrating the direct correlation of U87-GFPFLuc cell number with bioluminescence signal in vitro. Scale bar, 100 μm (TIFF 1458 kb)
11060_2012_1008_MOESM2_ESM.tif (3.1 mb)
Supplemental Figure 2 H&E staining of primary and recurrent tumors. Representative white light H&E images of brain sections from mice 2 weeks after primary tumor implantation (a) or tumor recurrence (b). Scale bars, 100 μm (TIFF 3223 kb)
Supplemental Movie 1

Image-guided surgical debulking. Representative movie depicting the initial stages of fluorescence guided surgical resection (MOV 4314 kb)

Supplemental Movie 2

Image-guided surgical debulking. Representative movie depicting the final stages fluorescence guided surgical resection when the tumor is excised from the brain leaving an empty cavity with residual tumors cells visible at the border of the cavity (MOV 1520 kb)


  1. 1.
    Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, Bigner DD (2009) Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18:1061–1083PubMedCrossRefGoogle Scholar
  2. 2.
    Asthagiri AR, Pouratian N, Sherman J, Ahmed G, Shaffrey ME (2007) Advances in brain tumor surgery. Neurol Clin 25(4):975–1003 Viii–ixPubMedCrossRefGoogle Scholar
  3. 3.
    Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198PubMedCrossRefGoogle Scholar
  4. 4.
    Stark AM, Nabavi A, Mehdorn HM, Blomer U (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63(2):162–169 discussion 169PubMedCrossRefGoogle Scholar
  5. 5.
    Fomchenko EI, Holland EC (2006) Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 12:5288–5297PubMedCrossRefGoogle Scholar
  6. 6.
    Jacobs VL, Valdes PA, Hickey WF, De Leo JA (2011) Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro 3:e00063PubMedCrossRefGoogle Scholar
  7. 7.
    Dai C, Holland EC (2001) Glioma models. Biochim Biophys Acta 1551:M19–M27PubMedGoogle Scholar
  8. 8.
    Krammer B, Plaetzer K (2008) ALA and its clinical impact, from bench to bedside. Photochem Photobiol Sci 7:283–289PubMedCrossRefGoogle Scholar
  9. 9.
    Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401PubMedCrossRefGoogle Scholar
  10. 10.
    Quant EC, Wen PY (2011) Response assessment in neuro-oncology. Curr Oncol Rep 13:50–56PubMedCrossRefGoogle Scholar
  11. 11.
    Mehta AI, Kanaly CW, Friedman AH, Bigner DD, Sampson JH (2011) Monitoring radiographic brain tumor progression. Toxins (Basel) 3:191–200Google Scholar
  12. 12.
    Akbar U, Jones T, Winestone J, Michael M, Shukla A, Sun Y, Duntsch C (2009) Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection. J Neurooncol 94:203–212PubMedCrossRefGoogle Scholar
  13. 13.
    Kauer TM, Figueiredo JL, Hingtgen S, Shah K (2011) Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas. Nat Neurosci 15(2):197–204PubMedCrossRefGoogle Scholar
  14. 14.
    Bello L, Giussani C, Carrabba G, Pluderi M, Lucini V, Pannacci M, Caronzolo D, Tomei G, Villani R, Scaglione F, Carroll RS, Bikfalvi A (2002) Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 8:3539–3548PubMedGoogle Scholar
  15. 15.
    Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez-Serrano A, Breakefield X, Weissleder R (2008) Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci 28:4406–4413PubMedCrossRefGoogle Scholar
  16. 16.
    Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26:397–409PubMedCrossRefGoogle Scholar
  17. 17.
    Hou LC, Veeravagu A, Hsu AR, Tse VC (2006) Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus 20:E5PubMedCrossRefGoogle Scholar
  18. 18.
    Hillier WF Jr (1954) Total left cerebral hemispherectomy for malignant glioma. Neurology 4:718–721PubMedCrossRefGoogle Scholar
  19. 19.
    Kanaly CW, Ding D, Mehta AI, Waller AF, Crocker I, Desjardins A, Reardon DA, Friedman AH, Bigner DD, Sampson JH (2011) A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One 6:e16031PubMedCrossRefGoogle Scholar
  20. 20.
    Nazzaro JM, Neuwelt EA (1990) The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73:331–344PubMedCrossRefGoogle Scholar
  21. 21.
    Quigley, Maroon JC (1991) The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 29(3):385–388 discussion 388-389PubMedCrossRefGoogle Scholar
  22. 22.
    Hess KR (1999) Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42:227–231PubMedCrossRefGoogle Scholar
  23. 23.
    Metcalfe SE, Grant R (2001) Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev (3):CD002034Google Scholar
  24. 24.
    Stummer W, Stocker S, Novotny A, Heimann A, Sauer O, Kempski O, Plesnila N, Wietzorrek J, Reulen HJ (1998) In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B 45:160–169PubMedCrossRefGoogle Scholar
  25. 25.
    Hingtgen SD, Kasmieh R, van de Water J, Weissleder R, Shah K (2010) A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy. Stem Cells 28:832–841PubMedCrossRefGoogle Scholar
  26. 26.
    Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS (2008) Molecular imaging in drug development. Nat Rev Drug Discov 7:591–607PubMedCrossRefGoogle Scholar
  27. 27.
    Heckl S, Pipkorn R, Nagele T, Vogel U, Kuker W, Voight K (2004) Molecular imaging: bridging the gap between neuroradiology and neurohistology. Histol Histopathol 19:651–668PubMedGoogle Scholar
  28. 28.
    Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD (2009) Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69(8):3472–3481PubMedCrossRefGoogle Scholar
  29. 29.
    Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164–176PubMedCrossRefGoogle Scholar
  30. 30.
    Taghva A, Khalessi AA, Kim PE, Liu CY, Apuzzo ML (2010) From atom to brain: applications of molecular imaging to neurosurgery. World Neurosurg 73:477–485PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Shawn Hingtgen
    • 1
  • Jose-Luiz Figueiredo
    • 1
  • Christian Farrar
    • 2
  • Matthias Duebgen
    • 1
  • Jordi Martinez-Quintanilla
    • 1
  • Deepak Bhere
    • 1
  • Khalid Shah
    • 1
    • 3
    • 4
    Email author
  1. 1.Molecular Neurotherapy and Imaging Laboratory, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  2. 2.Department of Radiology, Massachusetts General HospitalAthinoula A. Martinos Center for Biomedical Imaging, Harvard Medical SchoolBostonUSA
  3. 3.Department of Neurology, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  4. 4.Harvard Stem Cell Institute, Harvard UniversityCambridgeUSA

Personalised recommendations